TuBaFrost 4: Access rules and incentives for a European tumour bank
- 作者J.A. Lopez-Guerrero; P.H.J. Riegman; J.W. Oosterhuis; K.H. Lam; M.H.A. Oomen; A. Spatz; C. Ratcliffe; K. Knox; R. Mager; D. Kerr; F. Pezzella; B. van Damme; M. van de Vijver; H. van Boven; M.M. Morente; S. Alonso; D. Kerjaschki; J. Pammer; A. Carbone; A. Gloghini; I. Teodorovic; M. Isabelle; A. Passioukov; S. Lejeune; P. Therasse; E.-B. van Veen; W.N.M. Dinjens; A. Llombart-Bosch
- 卷第42卷
- 期第17期
- 印刷ISSN0959-8049
- 文件大小190.31KB
- 发表时间2006
- DOI10.1016/j.ejca.2006.04.030
Aurora kinase inhibitorsJ.J.E.M. Kitzen; M.J.A. de Jonge; J. Verweij · 2010
1256 POSTER Evaluation of Enrollment in Oncology Phase I Clinical TrialsA.J. van der Biessen; M.A. Cranendonk; B. van der Holt; J. Verweij; M.J.A. de Jonge; R.H.J. Mathijssen · 2011
The development of combination therapy involving camptothecins: a review of preclinical and early clinical studiesM.J.A. de Jonge; A. Sparreboom; J. Verweij · 1998
Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumoursJ.J.E.M. Kitzen; M.J.A. de Jonge; C.H.J. Lamers; F.A.L.M. Eskens; D. van der Biessen; L. van Doorn; J. ter Steeg; M. Brandely; Ch. Puozzo; J. Verweij · 2009
Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumoursM.J.A. de Jonge; H. Dumez; J. Verweij; S. Yarkoni; D. Snyder; D. Lacombe; S. Marréaud; T. Yamaguchi; C.J.A. Punt; A. van Oosterom · 2006
Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumoursM.J.A. de Jonge; H. Dumez; J.J.E.M. Kitzen; B. Beuselinck; J. Verweij; R. Courtney; A. Battista; N. Brega; P. Schöffski · 2011
Real-time pharmacokinetics guiding clinical decisions: phase I study of a weekly schedule of liposome encapsulated paclitaxel in patients with solid tumoursO. Soepenberg; A. Sparreboom; M.J.A. de Jonge; A.S.Th. Planting; G. de Heus; W.J. Loos; C.M. Hartman; C. Bowden; J. Verweij · 2004